Background: Peripheral blood stem cell (PBSC) mobilization is routinely undertaken prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A number of studies have identified risk factors for poor PBSC mobilization, however, little data exists to correlate mobilization with disease-specific outcomes in this patient population. Prospective work in MM has demonstrated similar outcomes in a homogenous patient population.
| I NT ROD UCTI ON
High dose chemotherapy with autologous stem cell transplantation (ASCT) remains an important component of the management of patients with multiple myeloma (MM) due to its safety and favorable impact on progression free survival (PFS) and overall survival (OS). [1] [2] [3] [4] [5] [6] As such, most providers consider ASCT to be the standard of care for consolidation; however, a proportion of patients will experience difficulty mobilizing peripheral blood stem cells (PBSC). [7] [8] [9] [10] Previously established risk factors for poor mobilization include multiple lines of chemotherapy, advanced age, thrombocytopenia, prior radiotherapy, and others. [10] [11] [12] [13] [14] [15] In MM, multiple studies reported lenalidomide use to be another risk factor for poor mobilization. [16] [17] [18] [19] Most studies use different definitions for poor mobilization in MM patients, mainly due to the practice of collecting upfront adequate numbers of stem cells for two transplants. [20] [21] [22] Poor mobilization prior to ASCT has important prognostic implications. In lymphoma, work from our institution demonstrated poor mobilizers (defined as inability to obtain 1 3 10 6 CD341 cells/kg ideal body weight [IBW] with two large volume apheresis) had a shortened PFS and OS compared to patients who were good mobilizers. 15 Similar work from the Cleveland Clinic linked 5 days of apheresis with a higher incidence of post ASCT relapse-related mortality and significantly shorter OS. 23 In patients with MM, the GIMEMA MMY-3006 trial evaluated outcomes of patients treated with bortezomib, thalidomide, dexamethasone (VTD) versus thalidomide and dexamethasone (TD), followed by cyclophosphamide (4 g/m 2 ) and granulocyte colony stimulating factor (G-CSF) 10 mcg/kg/day for PBSC mobilization. Patients in this study that failed to reach the collection target went on to experience an inferior time to disease progression, PFS, and OS. 24 The introduction and acceptance of the CXCR4 antagonist plerixafor has reduced the number of poor mobilizers and the incidence of mobilization failures. In a multicenter, double-blinded, placebo-controlled phase 3 study, a significantly higher percentage of MM patients treated with G-CSF plus plerixafor met the primary endpoint of collecting 6 3 10 6 CD341 cells/kg with 2 apheresis attempts (71.6% vs 34.4%). 25 Although plerixafor proved effective in increasing the PBSC collection yield, nearly one-third of patients still fell short of the collection target. Furthermore, it is not known if plerixafor mobilized and transplanted patients have improved PFS and OS. Both plerixafor 1 G-CSF or cyclophosphamide 1 G-CSF mobilization were reported to be effective mobilization methods to overcome poor mobilization in MM patients. [26] [27] [28] [29] [30] In this single institution analysis, we report our experience with poor PBSC mobilization in MM patients. The retrospective design of our study allowed us to collect more mature survival data, in a more heterogeneous patient population, than was feasible with the GIMEMA MMY-3006 trial. We hypothesize that poor PBSC mobilization will continue to be associated with an aggressive disease biology and shortened survival.
| P A TI ENTS A ND M ETHO DS
In this single institution analysis, approved by our Institutional Review Board (IRB201400571), we retrospectively studied the impact of poor PBSC mobilization on PFS and OS in MM patients undergoing PBSC mobilization in preparation for ASCT from January 1, 2001 through December 31, 2010. We subsequently evaluated clinical characteristics of these patient populations with the intention of validating prior risk factors and identifying new risks for poor PBSC mobilization.
Patients included in this analysis underwent standard induction therapy and were evaluated for ASCT according to institutional practices. Usually, patients underwent PBSC mobilization as soon as they achieved partial response (PR), either after 3-4 cycles of induction regimen, or occasionally after further therapy if PR was not achieved with first regimen. Further therapy was also offered to patients whose marrow at the time of evaluation had > 20% plasma cells.
All patients underwent apheresis in similar way using the same type of equipment. The apheresis was perform using COBE Spectra version 6.1 (TerumoBCT, Lakewood, CO). Fixed volume of 20 L was processed each day of apheresis through an internal jugular special catheter. The anticoagulant used during the procedure is anticoagulant citrate dextrose, formula A (ACD-A). PBSCs were mobilized using G-CSF 10 mcg/kg/day (without chemotherapy) and apheresis is started on the fifth day of G-CSF without prior checking of the CD341 cell content in the peripheral blood. CD34 was checked by flow cytometry on the final apheresis product each day. Plerixafor (given at 10 pm the evening before apheresis) was added to G-CSF for all second mobilization cycles, and also when the CD341 yield after first or second day of first apheresis (< 1 3 10 6 CD341 cells/kg IBW) suggested minimal target of 4 3 10 6 CD341 cells/kg IBW adequate for two ASCTs may not be achieved. Apheresis was attempted for up to five sequential days and a second mobilization cycle was scheduled if, in the judgement of the attending physician, it was necessary and/or appropriate to collect an adequate PBSC dose. After PBSC collection and appropriate quality control measures such as negative product cultures, patients are admitted to the hospital to receive conditioning therapy in accordance with the then-current standard practices and/or institutional clinical trials. [31] [32] [33] Response assessments were made in accordance with the International Myeloma Working Group Uniform Response Criteria. 34 Patients were offered post-HCT maintenance therapy at the discretion of the attending physician. For the purposes of this analysis, poor mobilizers are defined as patients that collected < 4 3 10 6 CD34 1 cells/kg IBW over maximum of 5 apheresis days, or those that required 2 mobilization cycles to achieve this target. All others were classified as good mobilizers. PFS is defined as the time from the start of induction therapy to documented relapse and is censored at the last clinic visit. OS is the time from diagnosis until patient death from any cause. Group characteristics are reported using descriptive statistics and comparisons between groups were undertaken using Fisher's exact test for categorical variables or a twosided student's t test for continuous variables. The Cox proportional hazards model is used for PFS and OS comparisons. Survival data are presented with Kaplan-Meier curves. Comparison of survival curves was done with the log-rank test. P values of <.05 are considered significant. To identify important risk factors that predict the mobilization status, multivariate logistic regression is performed. Multivariate Cox proportional hazards model is performed to assess known prognostic variables, PFS, and OS. For each multivariate analysis, a stepwise selection procedure (0.05 significance level for entering or remaining in the model) is used to build a final model with important risk factors and prognostic variables.
| R ES ULT S

| Patient characteristics
A total of 270 patients were identified; 242 (89.6%) patients were considered good mobilizers and 28 patients (10.4%) were poor mobilizers. Fourteen out of 28 poor mobilizers required 2nd mobilization cycle to achieve target cell dose. The mean age of the cohort at diagnosis was 56.9 6 9.1 years and the group was 56.7% male. Caucasians and African Americans were the predominant ethnicities in this analysis at 68.8% and 22.3%, respectively. Most patients had an IgG paraprotein (48.9%) followed by IgA (23.3%). The (Table  1) , including the proportion of patients receiving posttransplant maintenance and the time from diagnosis to transplant. Poor mobilization was associated with a trend toward a higher D-S disease stage (82.1% vs 65%, P 5 .088) and a higher incidence of relapse (81% vs 62%, respectively P 5 .059) in comparison to good mobilizers. Additional patient characteristics are summarized in Table 1 . However, cytogenetics and FISH results were not included due to missing such data on the majority of patients. This is possibly explained by the fact that we are mostly a tertiary referral center and thus it was up to the referring physicians to have this data collected and available. The same applies for the albumin and beta 2-microglobulin (B2M), both are reported separately in Table 1 , but were not available on all patients. Therefore, we could not provide staging per the International Staging System for all patients. The majority of patients (95.3%) went to ASCT with chemosensitive disease; the distribution of these patients was not significantly different between mobilization groups. At our program, we recommend non-lenalidomide containing induction therapy which is reflected by the finding that only 36 (10.6%) patients in the good mobilizers group and 6 (21%) in the poor mobilizers group received lenalidomide prior to PBSC collection. Poor mobilizers tended to receive more cycles of chemotherapy and lenalidomide-containing therapy prior to mobilization, however, these comparisons did not reach statistical significance (Table 2) . Post-ASCT response, the prescription of maintenance therapy, and the frequency of tandem ASCT was also similar between groups. A higher percentage of patients in the poor mobilization group were mobilized with G-CSF 1 plerixafor (25% vs 4.1%, P < .001) ( Table 2 ).
| Risk factors for poor mobilization
Poor mobilizers were significantly more likely to be male (71.5% vs 28.5%, P 5 .045), to receive a higher number of lines of chemotherapy prior to ASCT (median of 1 [range, 1-3] vs 2 [range, 1-4], P 5 .007), and to have a higher IBW (mean 63.0 vs 67.4 kg, P 5 .03). In addition, these patients were more likely to be older (mean 58.1 vs 61.4 years, P 5 .066), however, this did not reach statistical significance.
Since we calculate CD34 cell dose based on IBW according to our previous publication, 35 we hypothesized that poor mobilizers may have higher IBW. This was indeed the case, although did not hold true in multivariate analysis. In this analysis, obesity, prior radiotherapy and prior lenalidomide were not risk factors for poor mobilization (see Table 3 ). In a multivariate analysis, the use of plerixafor (Odds ratio 0.092, 95% CI 0.028-0.299, P < .0001) or high dose G-CSF >10 mcg/kg/day (Odds ratio 0.312, 95% CI 0.124-0.782, P 5 .013) significantly predicted for good mobilization, while > 2 prior lines of therapy (before ASCT) was the only independent factor predictive of poor mobilization (Odds ratio 1.857, 95% CI 1.163-2.966, P 5 .0095). When considering previously established risk factors including age, number of lines of chemotherapy, number of doses of lenalidomide, and prior external beam radiation, patients that were good mobilizers had a mean of 0.86 6 1.03 risk factors compared to 1.57 6 1.26 risk factors in poor mobilizers (P < .001). We fit a multivariate logistic regression model with all the above listed risk factors as covariates. The overall P values of the model is .0026 with max-rescaled R 2 (coefficient of determination) of 16.4%. In other words, these risk factors jointly explain about 16.4% variability in mobilization status.
| Survival analysis
Poor mobilization was associated with inferior survival outcomes. Survival analysis (Kaplan-Meier estimates) show that poor mobilizers had a shortened median PFS after ASCT compared to good mobilizers (24.3 vs 29.1 months, P 5 .0012, Figure 1 ) and experienced an inferior median OS (55.75 vs 93.5 months (P 5 .0005, Figure 2 ). The difference F IGUR E 1 Kaplan-Meier curve that shows poor mobilization to be associated with a significantly inferior PFS relative to good mobilizers (P 5 .0012). PFS is defined as the time in months from ASCT to relapse (ASCT to R)
is OS between the two groups was still significantly better in the good mobilizers group even after the removal of 35 patients (14.9% of the good mobilizers) who received tandem/second transplants (P < .001). In a multivariate analysis, only poor mobilization and disease remission status post ASCT, but not disease stage at diagnosis, significantly affected the OS, while all three characteristics significantly affected the PFS (Table 4) .
In a closer look at the effect of plerixafor on PFS and OS, we performed sub analysis on patients who received plerixafor for their PBSC mobilization in both groups. Seven patients (25%) in the poor mobilizers received plerixafor and had median OS of 52.8 months (range, 23.1-79.2) and PFS of 21.6 months (range, 17.3-50.4), while 10 patients (4.1%) in the good mobilizers received plerixafor and had median OS of 62.75 months (range, 11.7-180) with PFS of 24.6 months (range, 11-88.7) (P > .4948). We then asked the question whether adding plerixafor during mobilization (n 5 7) within the poor mobilizers group improves outcomes in comparison to those poor mobilizers receiving G-CSF only mobilized stem cell products (n 5 21). The median PFS was 21.6 (range, 17.3-50.4) and 38.1 (range, 8.9-102.4) months (P 5 .4077), while the median OS was 52.8 (range, 2) months (P 5 .4996), with and without plerixafor, respectively. As the good mobilizers who received plerixafor seems to have similar outcomes like the poor mobilizers, we added the 10 good mobilizers patients who received plerixafor to the poor mobilizers (n 5 38) and compared PFS and OS to those of the good mobilizers without the 10 plerixafor patients (n 5 232). Log rank test showed median PFS of 35 months for the expanded poor mobilizers group and 43.6 months for the modified good mobilizers (P 5 .0581, HR 5 1.498, 95% CI 0.984-2.617). However, the OS remained significantly better for the modified good mobilizers Group (93.5 months) over the expanded poor mobilizers Group (56.2 months) (P 5 .0094, HR5 1.728, 95% CI 1.81-3.285).
| D IS C US S I ON
In this analysis, we demonstrate that poor PBSC mobilization is a significant clinical problem in MM patients with incidence of 10.4% in our study presented here. We also demonstrate that poor mobilization is associated with inferior PFS and OS in MM patients undergoing ASCT, and that is regardless of the year in which ASCT took place. In addition to correlating mobilization with clinical outcomes, this analysis identifies number of prior lines of chemotherapy as an independent risk factor for poor PBSC mobilization.
To date, this is the largest retrospective analysis to evaluate the impact of mobilization on clinical outcomes in MM patients. Importantly, this work validates the findings from the phase 3, open-label, multicenter GIMEMA MMY-3006 (NCT01134484) study published in 2015. This trial assessed the efficacy and safety of VTD versus TD induction therapy prior to ASCT and reported that poor mobilizers experienced inferior outcomes, defined as 5-year rates of time to progression (TTP), PFS, and OS, relative to those that readily mobilized PBSCs. 24 Although retrospective, our analysis has few positive aspects that is usually lacking in prospective studies. Because our dataset includes patients that were followed at our institution over a 10-year period, we were able to capture a wide range of induction regimens and salvage therapies, as well as their impact on PBSC mobilization. The end result is a heterogeneous patient population that is generalizable to clinical practice. Furthermore, this approach facilitates the assessment of a variety of risk factors, in an adequately sized patient population, to allow for correlations with patient outcomes.
There are also limitations of our study that should be considered. The obvious criticism is that the retrospective approach precludes standardized disease assessments and that mobilization practices/regimens are not uniform. Our definition of poor mobilizers was a practical one but slightly different from other definitions used in previous publications. Furthermore, in our program, we recommend non-lenalidomide containing induction therapy, mainly cyclophosphamide/bortezomib/dexamethasone, which may explain the lower number of patients who received lenalidomide in their first induction regimen and possibly the relatively lower frequency of poor mobilizers (10.4%), whereas many other studies reported > 15% incidence. 21, 22 Another possible limitation is the relatively small number of patients treated with CXCR4 antagonist plerixafor. Due to its effectiveness in reducing the number of poor mobilizers, many institutions now routinely utilize plerixafor for PBSC mobilization. Even with this approach, a subset of patients will still meet the criteria for poor mobilization. In our dataset, 7/28 (25%) were poor mobilizers in spite of receiving the plerixafor. This emphasizes that even with plerixafor, patients may not readily mobilize PBSCs for ASCT and still go on to experience inferior survival outcomes. Our analysis shows that patient receiving plerixafor whether in the poor or good mobilizers groups, have similar OS which is lower than the OS seen for the good mobilizers and is in line with the OS of the poor mobilizers group. Furthermore, there was a trend for worse OS in patients receiving plerixafor versus those who did not within the poor mobilizers group. However, these results should be cautiously interpreted and further confirmation should be sought from other studies. This study suggests that PBSC mobilization may be an important and under recognized predictor of MM biology. Our finding that poor mobilizers were more likely to receive additional lines of chemotherapy before proceeding to ASCT is consistent with this observation. Receiving more lines of chemotherapy before transplant could be sign of disease refractoriness, although it could also be due to practice pattern, insurance delays, or patient choice. Our data shows that it might be the former as poor mobilizers were more likely to have minimal response or worse (21.6%) at the time of ASCT (Table 2 ) versus 13% in the good mobilizers (P 5 .5614). Furthermore, another potentially biologically important factor in the prognosis of poor mobilizers is the fact that 25% of them were still considered poor mobilizers despite the use of plerixafor. As we suggested previously in our lymphoma study, 15 some of these patients may have a real deficiency of stem cells, which can possibly compromise the success of subsequent treatments and result in immunodeficiency state that affect the natural history of the disease. Indeed, most patients in the poor mobilizers group, with the exception of one, died of progressive disease. Previously established risk factors for poor PBSC mobilization including age, prior radiotherapy, and lenalidomide exposure were not independently associated with poor mobilization in this analysis. In a cumulative risk model, however, these were important contributors suggesting that the relatively small population of poor mobilizers in our study may have prevented these comparisons from reaching statistical significance.
In conclusion, our work confirms the findings of the GIMEMA MMY-3006 investigators, and is in line with lymphoma studies that correlate poor PBSC mobilization with inferior disease-specific outcomes. Thus, MM patients that experience difficulty in collecting PBSCs should be viewed as a high-risk population and should receive aggressive post-ASCT maintenance therapy and close disease surveillance.
